https://www.selleckchem.com/pr....oducts/lazertinib-yh
754), followed by the CAD consortium basic (0.736), and finally, the DF model (0.718). Whereas the CAD consortium models more accurately classified patients without any CAD or nonobstructive CAD as low-risk patients, the DF model more accurately classified high-risk patients with obstructive CAD. The net reclassification improvement of CAD consortium basic and clinical models were 24.7% and 27.9%, respectively. CONCLUSIONS Compared with the DF model, the CAD consortium clinical model appears to improve the prediction
Beğen
Yorum Yap
Paylaş
